In this real-world evidence blog post, Worldwide Clinical Trials discusses the new, viable approaches to improving medical decision-making that are at the forefront, in addition to making the case for “observentional” research.
Read More
In this blog post, Worldwide Clinical Trials previews its upcoming eBook, “7 Trends in Early Phase Clinical Trials and How to Make Them Work for You.”
Read More
Investigators, clinicians, laboratory technicians, clinical research professionals, nurses, and pharmacists from around the world gathered in Houston to share therapeutic advances for hematologic malignancies. Dr. Michael Trigg shares his thoughts and experience from the conference.
Read More
Extensive research and drug development lies at the core of modern medicine. However, when it comes to an orphan indication or rare disease research and drug development, big pharmaceutical organizations are reluctant to invest because of perceived limited commercial viability. Our latest blog explores why it matters to invest in orphan disease research and development and what it means for clinical researchers in the oncology space.
Read More
FDA approves oncology drugs that target an unmet need in the marketplace – attacking the specific genetic drivers of cancer, rather than the type of tumor itself.
Read More
It’s Rare Disease Day 2019! In this blog post, Worldwide Clinical Trials employee Jackie Brusch talks about her uncommonly rare disorder, what she wants people to know about rare diseases, and how Worldwide is advancing rare disease clinical research.
Read More
